Mankit Law is a Senior Associate at Pappas Capital, where he is actively involved in sourcing and evaluating investment opportunities and in supporting portfolio companies. Among the many Pappas Capital portfolio companies with which Mankit has been involved, he played a key role in the firm’s successful investments in Kezar Life Sciences (NASDAQ: KZR), Amplyx Pharmaceuticals, Reneo Pharmaceuticals, VelosBio, 4D Molecular Therapeutics, Ribometrix, and Mirum Pharmaceuticals. In addition, Mankit is involved in the management of the Chiesi Ventures Fund — a specialized fund focused on investment opportunities in the arena of orphan / rare diseases, and he supports the creation and execution of business development strategies of the Catalyst Fund — a collaborative initiative established with the Wake Forest Baptist Medical Center to accelerate the translation of the Center's new research discoveries and inventions into innovative new medical products.
Before joining Pappas Capital, Mankit was a commercialization and licensing manager in the Office of Technology Development at the University of North Carolina at Chapel Hill. During his tenure in the UNC technology transfer office, he led the negotiation of contracts governing the development, allocation, and commercialization of existing and prospective intellectual property rights for a portfolio of life sciences technologies. He also served as an active member of the Association of University Technology Managers and the Licensing Executives Society. Before joining the Office of Technology Development, Mankit was the Innovation and Entrepreneurship Fellow of the UNC Eshelman School of Pharmacy, where he was a key advisor for the School’s inventors and start-up ventures. In this role, he served as an intellectual property scout, a liaison between the School and its development partners, and an administrator for the School’s innovation development and entrepreneurship educational programs. Earlier in his career, Mankit was a postdoctoral fellow of the UNC Lineberger Comprehensive Cancer Center. With a decade of experience as a medical technologist and researcher, he has authored five peer-reviewed publications and has been given the Ruth L. Kirschstein National Research Service Award from the National Cancer Institute.
Mankit earned a B.S. in Biotechnology and a Ph.D. in Immunology and Infectious Diseases from the Pennsylvania State University and a M.B.A. from the University of North Carolina’s Kenan-Flagler Business School.